Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Pediatric Participants With Moderate-to-Severe Atopic Dermatitis
NCT05559359Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Oct 2022; status: active, not recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05559359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559359.